EP3313427A4 - Peptides thérapeutiques et leurs procédés d'utilisation - Google Patents

Peptides thérapeutiques et leurs procédés d'utilisation Download PDF

Info

Publication number
EP3313427A4
EP3313427A4 EP16815459.9A EP16815459A EP3313427A4 EP 3313427 A4 EP3313427 A4 EP 3313427A4 EP 16815459 A EP16815459 A EP 16815459A EP 3313427 A4 EP3313427 A4 EP 3313427A4
Authority
EP
European Patent Office
Prior art keywords
methods
therapeutic peptides
peptides
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16815459.9A
Other languages
German (de)
English (en)
Other versions
EP3313427A2 (fr
Inventor
James Olson
Andrew David STRAND
Emily June GIRARD
Roland STRONG
Christopher Mehlin
Colin CORRENTI
Andrew James MHYRE
Mi-youn BRUSNIAK
Theo SOTTERO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Priority claimed from PCT/US2016/039431 external-priority patent/WO2016210376A2/fr
Publication of EP3313427A2 publication Critical patent/EP3313427A2/fr
Publication of EP3313427A4 publication Critical patent/EP3313427A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16815459.9A 2015-06-26 2016-06-24 Peptides thérapeutiques et leurs procédés d'utilisation Withdrawn EP3313427A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562185529P 2015-06-26 2015-06-26
US201562185527P 2015-06-26 2015-06-26
US201562239743P 2015-10-09 2015-10-09
US201562239739P 2015-10-09 2015-10-09
US201662322724P 2016-04-14 2016-04-14
PCT/US2016/039431 WO2016210376A2 (fr) 2015-06-26 2016-06-24 Peptides thérapeutiques et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3313427A2 EP3313427A2 (fr) 2018-05-02
EP3313427A4 true EP3313427A4 (fr) 2018-12-26

Family

ID=61661067

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16815459.9A Withdrawn EP3313427A4 (fr) 2015-06-26 2016-06-24 Peptides thérapeutiques et leurs procédés d'utilisation

Country Status (2)

Country Link
EP (1) EP3313427A4 (fr)
CN (1) CN107847554A (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003345A (es) * 2018-09-25 2021-07-02 Univ Emory Acidos nucleicos para reconocimiento e integracion celular.
TWI715927B (zh) * 2019-02-01 2021-01-11 國立清華大學 組合物用於製備治療癌細胞的藥物的用途
CN112028981B (zh) * 2020-09-08 2022-03-15 湖州眺旺生物科技有限公司 重组白额高脚蛛毒素多肽及其制备方法
CN114031678A (zh) * 2021-12-08 2022-02-11 中国科学院新疆理化技术研究所 一种条斑钳蝎毒素多肽组分的制备方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064658A1 (fr) * 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Protéines de fusion comprenant un peptide knottine modifié et utilisations de celles-ci
US20130280281A1 (en) * 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
WO2014063012A1 (fr) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Miniprotéines knottines conjuguées contenant des acides aminés non naturels
WO2014093406A1 (fr) * 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Procédés de criblage
WO2017100700A2 (fr) * 2015-12-11 2017-06-15 Fred Hutchinson Cancer Research Center Peptides pour thérapie rénale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
CN102174080B (zh) * 2010-09-19 2014-07-09 复旦大学 具有脑靶向递药特性的多肽及其制备方法
CN103083689B (zh) * 2011-11-01 2016-08-03 复旦大学 一种用于脑肿瘤诊断的跨血脑屏障靶向多模态纳米药物
EP3046572A4 (fr) * 2013-09-17 2017-06-28 Blaze Bioscience, Inc. Conjugués de chlorotoxine et procédés pour les utiliser

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280281A1 (en) * 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
WO2012064658A1 (fr) * 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Protéines de fusion comprenant un peptide knottine modifié et utilisations de celles-ci
WO2014063012A1 (fr) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Miniprotéines knottines conjuguées contenant des acides aminés non naturels
WO2014093406A1 (fr) * 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Procédés de criblage
WO2017100700A2 (fr) * 2015-12-11 2017-06-15 Fred Hutchinson Cancer Research Center Peptides pour thérapie rénale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 10 August 2017 (2017-08-10), "Pharmaceutical composition preparing knotted peptide, SEQ ID 41.", retrieved from EBI accession no. GSP:BDZ69828 Database accession no. BDZ69828 *
DATABASE Geneseq [online] 31 July 2014 (2014-07-31), "Chlorotoxin (CTX) peptide variant, SEQ 39.", retrieved from EBI accession no. GSP:BBI66026 Database accession no. BBI66026 *
DATABASE Geneseq [online] 31 July 2014 (2014-07-31), "Chlorotoxin (CTX) peptide variant, SEQ 44.", retrieved from EBI accession no. GSP:BBI66031 Database accession no. BBI66031 *

Also Published As

Publication number Publication date
CN107847554A (zh) 2018-03-27
EP3313427A2 (fr) 2018-05-02

Similar Documents

Publication Publication Date Title
EP3509615A4 (fr) Peptides stables et leurs procédés d'utilisation
EP3245291A4 (fr) Nouvelles micro-dystrophines et méthodes d'utilisation associées
EP3328419A4 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3302562A4 (fr) Molécules se liant à lag-3 et méthodes d'utilisation de ces dernières
EP3359168A4 (fr) Composés thérapeutiques et procédés
EP3209681A4 (fr) Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation
IL256515A (en) Therapeutic peptides and methods of use thereof
EP3097122A4 (fr) Protéines de liaison et leurs procédés d'utilisation
EP3177638A4 (fr) Peptides de ciblage et méthodes d'utilisation
EP3131566A4 (fr) Peptides de liaison a l'integrine pegyles aux deux extremites terminalesleurs procedes d'utilisation
EP3220953A4 (fr) Compositions et procédés d'utilisation de peptides thérapeutiques en relation avec p53 et de leurs analogues
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3116898A4 (fr) Utilisation de la protéine m013 exprimée par un vecteur aav comme agent thérapeutique anti-inflammatoire
EP3274472A4 (fr) Peptides antimicrobiens et leurs méthodes d'utilisations
EP3526205A4 (fr) Composés thérapeutiques et leurs procédés d'utilisation
EP3285805A4 (fr) Anticorps thérapeutiques et utilisations de ceux-ci
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
EP3525855A4 (fr) Inhalateur et procédés d'utilisation associés
EP3389705A4 (fr) Immunothérapie basée sur la listéria et ses méthodes d'utilisation
EP3265476A4 (fr) Variants de protoxine ii et méthodes d'utilisation
EP3172224A4 (fr) Variants de protéines de liaison au facteur h et procédés d'utilisation de ceux-ci
EP3270918A4 (fr) Anticorps anti-met et procédés d'utilisation de ceux-ci
EP3215172A4 (fr) Modifications et utilisations de peptides de conotoxine
EP3277304A4 (fr) Variants de protoxine ii et leurs méthodes d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171208

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181128

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/16 20060101AFI20181123BHEP

Ipc: A61K 49/14 20060101ALI20181123BHEP

Ipc: A61K 38/00 20060101ALI20181123BHEP

Ipc: C07K 14/435 20060101ALI20181123BHEP

Ipc: A61K 38/03 20060101ALI20181123BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210202